Information on new approvals and medication safety
Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances
Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.
The American College of Rheumatology (ACR) can Help Combat Insurance Frustrations
When it comes to dealing with insurance companies, the rules seem to change frequently and always in an arbitrary and capricious way. The ACR is trying its best to protect rheumatologists, but we need your help!
Reflections on Living with Lupus, and on Treating It
There are some people whose purpose in life is to entertain. Some of us are fortunate to have them as our patients.
American College of Rheumatology (ACR) Advocates for Improved Access to Critical Treatments
The ACR is promoting federal legislation to eliminate high cost sharing for specialty tier medications in all states.
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Pinpoint Cognitive Dysfunction in Patients with Lupus
More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Ethics Forum: The Ethical Pitfalls of Clinical Trials
Your patient is deciding whether to enroll in a clinical trial at your institution and wants your advice about whether to participate.
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- Next Page »